Ligands of the Natural Killer (NK) Cell Surface Marker CD27 and Therapeutic Uses Thereof,
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Mar 3, 2011
app pub date -
Feb 16, 2009
filing date -
Feb 15, 2008
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention relates to the modulation of Natural Killer (NK) cells in vitro or in vivo through the use of activating or inhibiting ligands of CD27, such as antibodies, for a regulation of the immune response against several different diseases, such as viral infections, cancer, bacterial infections, sepsis as well as immunological diseases. In a preferred embodiment, the inventors were able to improve the host resistance against Influenza virus and cancer through the application of anti-CD27 antibodies. In a different setting the inventors were able to prevent the onset of a lethal bacterial sepsis by preventing the activation of NK cells via CD27. The invention furthermore relates to screening assays for ligands of the surface marker CD27.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully